SHANGHAI, Oct. 9, 2011 /PRNewswire-Asia/ -- Vaccines made in China will now be supplied through United Nations (UN) agencies to developing countries, after recognition from the World Health Organisation (WHO) that China's State Food and Drug Administration (SFDA) has complied with international standards for vaccine regulation. The acknowledgement on China's regulatory system is a precondition that could lead to the UN purchasing individual vaccines from Chinese vaccine makers. For this to occur, the manufacturers also have to pass the approval for China's new version of GMP (Good Manufacturing Practice) for the Chinese pharmaceutical industry that was released at the end of February. On the other hand, China's vaccine industry is driven by novel technologies, especially by recent technological advances in vaccine research, production and distribution.
Organized by Global Leaders Institute, more than 300 of the world's vaccine business leaders, researchers, policy makers, and advocates will be in Shanghai this November 29 and 30 attending VacChina 2011, the only international meeting in China devoted to vaccine development opportunity in China. The objective of this conference is to provide communication, education and networking opportunities for business leaders and scientists engaged in vaccine development whether in academia, biotech or industry.
This year's anniversary conference features a workshop on Vaccine Manufacturing and WHO pre-qualification. The workshop will focus on the technologies and challenges of vaccine manufacturing in today's marketplace including quality, safety, policy, and examples from the industry. Besides, VacChina 2011 provides a comprehensive, in-depth analysis of China's vaccine market, new vaccine targets and methods of delivery, regulatory and funding initiatives, as well as following issues:
- WHO pre-qualification requirements and details
- Updates on cGMP and relate